NCT04313504View on ClinicalTrials.gov

Study Evaluating the Efficacy of Niraparib and Dostarlimab (TSR-042) in Recurrent/Metastatic HNSCC

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

23

Participants

Timeline

Start Date

November 4, 2020

Primary Completion Date

June 1, 2024

Study Completion Date

June 1, 2025

Conditions

Head and Neck Cancer

Interventions

DRUG

Niraparib

Niraparib \& Dostarlimab combination

DRUG

Dostarlimab

Niraparib \& Dostarlimab combination

Trial Locations (1)

45219

University of Cincinnati Medical Center, Cincinnati

Sponsors

Collaborators (1)

GlaxoSmithKline

All Listed Sponsors

collaborator

GlaxoSmithKline

INDUSTRY

lead

Trisha Wise-Draper

OTHER

NCT04313504 - Study Evaluating the Efficacy of Niraparib and Dostarlimab (TSR-042) in Recurrent/Metastatic HNSCC | Biotech Hunter | Biotech Hunter